Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


Oliena Studio

Stroke and language recovery: 9000+ videos

EspañolItalianoSarduEnglish | PDF+


  Lung Cancer

  Free Subscription


Articles published in Br J Cancer

Retrieve available abstracts of 58 articles:
HTML format
Text format



Single Articles


    August 2019
  1. YONEDA K, Kuwata T, Kanayama M, Mori M, et al
    Alteration in tumoural PD-L1 expression and stromal CD8-positive tumour-infiltrating lymphocytes after concurrent chemo-radiotherapy for non-small cell lung cancer.
    Br J Cancer. 2019 Aug 7. pii: 10.1038/s41416-019-0541.
    PubMed     Text format     Abstract available


    July 2019
  2. LAHEURTE C, Dosset M, Vernerey D, Boullerot L, et al
    Distinct prognostic value of circulating anti-telomerase CD4(+) Th1 immunity and exhausted PD-1(+)/TIM-3(+) T cells in lung cancer.
    Br J Cancer. 2019 Jul 30. pii: 10.1038/s41416-019-0531.
    PubMed     Text format     Abstract available


  3. GROEN HJM, van der Heijden EHFM, Klinkenberg TJ, Biesma B, et al
    Randomised phase 3 study of adjuvant chemotherapy with or without nadroparin in patients with completely resected non-small-cell lung cancer: the NVALT-8 study.
    Br J Cancer. 2019 Jul 24. pii: 10.1038/s41416-019-0533.
    PubMed     Text format     Abstract available


    June 2019
  4. MORGENSZTERN D, Rose M, Waqar SN, Morris J, et al
    RRx-001 followed by platinum plus etoposide in patients with previously treated small-cell lung cancer.
    Br J Cancer. 2019 Jun 24. pii: 10.1038/s41416-019-0504.
    PubMed     Text format     Abstract available


    May 2019
  5. SELLERS K, Allen TD, Bousamra M 2nd, Tan J, et al
    Metabolic reprogramming and Notch activity distinguish between non-small cell lung cancer subtypes.
    Br J Cancer. 2019 May 22. pii: 10.1038/s41416-019-0464.
    PubMed     Text format     Abstract available


    April 2019
  6. HEIM L, Kachler K, Siegmund R, Trufa DI, et al
    Increased expression of the immunosuppressive interleukin-35 in patients with non-small cell lung cancer.
    Br J Cancer. 2019 Apr 8. pii: 10.1038/s41416-019-0444.
    PubMed     Text format     Abstract available


    March 2019
  7. CREELAN BC, Gray JE, Tanvetyanon T, Chiappori AA, et al
    Phase 1 trial of dasatinib combined with afatinib for epidermal growth factor receptor- (EGFR-) mutated lung cancer with acquired tyrosine kinase inhibitor (TKI) resistance.
    Br J Cancer. 2019 Mar 18. pii: 10.1038/s41416-019-0428.
    PubMed     Text format     Abstract available


    February 2019
  8. WU SR, Lin CH, Shih HP, Ko CJ, et al
    HAI-2 as a novel inhibitor of plasmin represses lung cancer cell invasion and metastasis.
    Br J Cancer. 2019 Feb 15. pii: 10.1038/s41416-019-0400.
    PubMed     Text format     Abstract available


  9. KIM SH, Go SI, Song DH, Park SW, et al
    Prognostic impact of CD8 and programmed death-ligand 1 expression in patients with resectable non-small cell lung cancer.
    Br J Cancer. 2019 Feb 12. pii: 10.1038/s41416-019-0398.
    PubMed     Text format     Abstract available


    November 2018
  10. TSE LA, Lin X, Li W, Qiu H, et al
    Smoking cessation sharply reduced lung cancer mortality in a historical cohort of 3185 Chinese silicotic workers from 1981 to 2014.
    Br J Cancer. 2018 Nov 13. pii: 10.1038/s41416-018-0292.
    PubMed     Text format     Abstract available


  11. TIBALDI C, Camerini A, Tiseo M, Mazzoni F, et al
    Cytidine deaminase enzymatic activity is a prognostic biomarker in gemcitabine/platinum-treated advanced non-small-cell lung cancer: a prospective validation study.
    Br J Cancer. 2018 Nov 8. pii: 10.1038/s41416-018-0307.
    PubMed     Text format     Abstract available


    October 2018
  12. PASSIGLIA F, Cappuzzo F, Alabiso O, Bettini AC, et al
    Efficacy of nivolumab in pre-treated non-small-cell lung cancer patients harbouring KRAS mutations.
    Br J Cancer. 2018 Oct 31. pii: 10.1038/s41416-018-0234.
    PubMed     Text format     Abstract available


  13. BECKWITT CH, Clark AM, Ma B, Whaley D, et al
    Statins attenuate outgrowth of breast cancer metastases.
    Br J Cancer. 2018;119:1094-1105.
    PubMed     Text format     Abstract available


    September 2018
  14. SASAKI T, Seto T, Yamanaka T, Kunitake N, et al
    A randomised phase II trial of S-1 plus cisplatin versus vinorelbine plus cisplatin with concurrent thoracic radiotherapy for unresectable, locally advanced non-small cell lung cancer: WJOG5008L.
    Br J Cancer. 2018 Sep 12. pii: 10.1038/s41416-018-0243.
    PubMed     Text format     Abstract available


    August 2018
  15. EL-KHOURY V, Beland M, Schritz A, Kim SY, et al
    Identification of beta-arrestin-1 as a diagnostic biomarker in lung cancer.
    Br J Cancer. 2018 Aug 6. pii: 10.1038/s41416-018-0200.
    PubMed     Text format     Abstract available


    June 2018
  16. ZHENG R, Du M, Zhang B, Xin J, et al
    Body mass index (BMI) trajectories and risk of colorectal cancer in the PLCO cohort.
    Br J Cancer. 2018 Jun 6. pii: 10.1038/s41416-018-0121.
    PubMed     Text format     Abstract available


    May 2018
  17. ABOU FAYCAL C, Brambilla E, Agorreta J, Lepeltier N, et al
    The sVEGFR1-i13 splice variant regulates a beta1 integrin/VEGFR autocrine loop involved in the progression and the response to anti-angiogenic therapies of squamous cell lung carcinoma.
    Br J Cancer. 2018 May 24. pii: 10.1038/s41416-018-0128.
    PubMed     Text format     Abstract available


  18. GAO F, Alwhaibi A, Artham S, Verma A, et al
    Endothelial Akt1 loss promotes prostate cancer metastasis via beta-catenin-regulated tight-junction protein turnover.
    Br J Cancer. 2018 May 14. pii: 10.1038/s41416-018-0110.
    PubMed     Text format     Abstract available


    April 2018
  19. BINS S, Basak EA, El Bouazzaoui S, Koolen SLW, et al
    Association between single-nucleotide polymorphisms and adverse events in nivolumab-treated non-small cell lung cancer patients.
    Br J Cancer. 2018 Apr 26. pii: 10.1038/s41416-018-0074.
    PubMed     Text format     Abstract available


  20. DOHERTY JA, Grieshober L, Houck JR, Barnett MJ, et al
    Nested case-control study of telomere length and lung cancer risk among heavy smokers in the beta-Carotene and Retinol Efficacy Trial.
    Br J Cancer. 2018 Apr 19. pii: 10.1038/s41416-018-0075.
    PubMed     Text format     Abstract available


    March 2018
  21. GHOSH KM, Lee LH, Beckingsale TB, Gerrand CH, et al
    Indeterminate nodules in osteosarcoma: what's the follow-up?
    Br J Cancer. 2018;118:634-638.
    PubMed     Text format     Abstract available


  22. DI GIROLAMO C, Walters S, Gildea C, Benitez Majano S, et al
    Which patients are not included in the English Cancer Waiting Times monitoring dataset, 2009-2013? Implications for use of the data in research.
    Br J Cancer. 2018;118:733-737.
    PubMed     Text format     Abstract available


  23. DEL RE M, Marconcini R, Pasquini G, Rofi E, et al
    PD-L1 mRNA expression in plasma-derived exosomes is associated with response to anti-PD-1 antibodies in melanoma and NSCLC.
    Br J Cancer. 2018 Mar 6. pii: bjc20189. doi: 10.1038/bjc.2018.
    PubMed     Text format     Abstract available


    February 2018
  24. HAN B, Li K, Zhao Y, Li B, et al
    Anlotinib as a third-line therapy in patients with refractory advanced non-small-cell lung cancer: a multicentre, randomised phase II trial (ALTER0302).
    Br J Cancer. 2018 Feb 13. pii: bjc2017478. doi: 10.1038/bjc.2017.
    PubMed     Text format     Abstract available


  25. YUZHALIN AE, Urbonas T, Silva MA, Muschel RJ, et al
    A core matrisome gene signature predicts cancer outcome.
    Br J Cancer. 2018;118:435-440.
    PubMed     Text format     Abstract available


    January 2018
  26. SUN JM, Lee KH, Kim BS, Kim HG, et al
    Pazopanib maintenance after first-line etoposide and platinum chemotherapy in patients with extensive disease small-cell lung cancer: a multicentre, randomised, placebo-controlled Phase II study (KCSG-LU12-07).
    Br J Cancer. 2018 Jan 30. pii: bjc2017465. doi: 10.1038/bjc.2017.
    PubMed     Text format     Abstract available


  27. ANTONIO M, Saldana J, Linares J, Ruffinelli JC, et al
    Geriatric assessment may help decision-making in elderly patients with inoperable, locally advanced non-small-cell lung cancer.
    Br J Cancer. 2018 Jan 30. pii: bjc2017455. doi: 10.1038/bjc.2017.
    PubMed     Text format     Abstract available


  28. GADGEEL S, Shaw AT, Barlesi F, Crino L, et al
    Cumulative incidence rates for CNS and non-CNS progression in two phase II studies of alectinib in ALK-positive NSCLC.
    Br J Cancer. 2018;118:38-42.
    PubMed     Text format     Abstract available


    November 2017
  29. NANJO S, Hata A, Okuda C, Kaji R, et al
    Standard-dose osimertinib for refractory leptomeningeal metastases in T790M-positive EGFR-mutant non-small cell lung cancer.
    Br J Cancer. 2017 Nov 30. pii: bjc2017394. doi: 10.1038/bjc.2017.
    PubMed     Text format     Abstract available


    October 2017
  30. THALER J, Sigel C, Beasley MB, Wisnivesky J, et al
    Clinically significant mutations in HIV-infected patients with lung adenocarcinoma.
    Br J Cancer. 2017;117:1392-1395.
    PubMed     Text format     Abstract available


  31. O'SULLIVAN D, Dowling P, Joyce H, McAuley E, et al
    A novel inhibitory anti-invasive MAb isolated using phenotypic screening highlights AnxA6 as a functionally relevant target protein in pancreatic cancer.
    Br J Cancer. 2017;117:1326-1335.
    PubMed     Text format     Abstract available


  32. NI Z, Yao C, Zhu X, Gong C, et al
    Ailanthone inhibits non-small cell lung cancer cell growth through repressing DNA replication via downregulating RPA1.
    Br J Cancer. 2017 Oct 12. doi: 10.1038/bjc.2017.
    PubMed     Text format     Abstract available


  33. VAHL JM, Friedrich J, Mittler S, Trump S, et al
    Interleukin-10-regulated tumour tolerance in non-small cell lung cancer.
    Br J Cancer. 2017 Oct 10. doi: 10.1038/bjc.2017.
    PubMed     Text format     Abstract available


  34. GABASA M, Ikemori R, Hilberg F, Reguart N, et al
    Nintedanib selectively inhibits the activation and tumour-promoting effects of fibroblasts from lung adenocarcinoma patients.
    Br J Cancer. 2017;117:1128-1138.
    PubMed     Text format     Abstract available


    September 2017
  35. GREYSTOKE A, Steele N, Arkenau HT, Blackhall F, et al
    SELECT-3: a phase I study of selumetinib in combination with platinum-doublet chemotherapy for advanced NSCLC in the first-line setting.
    Br J Cancer. 2017;117:938-946.
    PubMed     Text format     Abstract available


  36. KOSHIARIS C, Aveyard P, Oke J, Ryan R, et al
    Smoking cessation and survival in lung, upper aero-digestive tract and bladder cancer: cohort study.
    Br J Cancer. 2017 Sep 12. doi: 10.1038/bjc.2017.
    PubMed     Text format     Abstract available


  37. KLIMOV S, Rida PC, Aleskandarany MA, Green AR, et al
    Novel immunohistochemistry-based signatures to predict metastatic site of triple-negative breast cancers.
    Br J Cancer. 2017;117:826-834.
    PubMed     Text format     Abstract available


    August 2017
  38. LI M, Yang J, Zhou W, Ren Y, et al
    Activation of an AKT/FOXM1/STMN1 pathway drives resistance to tyrosine kinase inhibitors in lung cancer.
    Br J Cancer. 2017 Aug 29. doi: 10.1038/bjc.2017.
    PubMed     Text format     Abstract available


  39. CALLAHAN CL, Schwartz K, Ruterbusch JJ, Shuch B, et al
    Leukocyte telomere length and renal cell carcinoma survival in two studies.
    Br J Cancer. 2017;117:752-755.
    PubMed     Text format     Abstract available


  40. ADLER NR, Wolfe R, Kelly JW, Haydon A, et al
    Tumour mutation status and sites of metastasis in patients with cutaneous melanoma.
    Br J Cancer. 2017 Aug 8. doi: 10.1038/bjc.2017.
    PubMed     Text format     Abstract available


  41. CIULEANU TE, Ahmed S, Kim JH, Mezger J, et al
    Randomised Phase 2 study of maintenance linsitinib (OSI-906) in combination with erlotinib compared with placebo plus erlotinib after platinum-based chemotherapy in patients with advanced non-small cell lung cancer.
    Br J Cancer. 2017 Aug 3. doi: 10.1038/bjc.2017.
    PubMed     Text format     Abstract available


    July 2017
  42. ALEXANDER M, Wolfe R, Ball D, Conron M, et al
    Lung cancer prognostic index: a risk score to predict overall survival after the diagnosis of non-small-cell lung cancer.
    Br J Cancer. 2017 Jul 20. doi: 10.1038/bjc.2017.
    PubMed     Text format     Abstract available


  43. WINTHER-LARSEN A, Demuth C, Fledelius J, Madsen AT, et al
    Correlation between circulating mutant DNA and metabolic tumour burden in advanced non-small cell lung cancer patients.
    Br J Cancer. 2017 Jul 6. doi: 10.1038/bjc.2017.
    PubMed     Text format     Abstract available


    June 2017
  44. WEISS GJ, Waypa J, Blaydorn L, Coats J, et al
    A phase Ib study of pembrolizumab plus chemotherapy in patients with advanced cancer (PembroPlus).
    Br J Cancer. 2017;117:33-40.
    PubMed     Text format     Abstract available


  45. SAMARENDRA H, Jones K, Petrinic T, Silva MA, et al
    A meta-analysis of CXCL12 expression for cancer prognosis.
    Br J Cancer. 2017;117:124-135.
    PubMed     Text format     Abstract available


  46. CHERNYAVSKIY P, Edmondson EF, Weil MM, Little MP, et al
    High-energy particle beam and gamma radiation exposure, familial relatedness and cancer in mice.
    Br J Cancer. 2017;117:41-50.
    PubMed     Text format     Abstract available


  47. PEDERSEN AB, Horvath-Puho E, Ehrenstein V, Rorth M, et al
    Frozen shoulder and risk of cancer: a population-based cohort study.
    Br J Cancer. 2017;117:144-147.
    PubMed     Text format     Abstract available


  48. BARRERA L, Montes-Servin E, Hernandez-Martinez JM, Garcia-Vicente MLA, et al
    CD47 overexpression is associated with decreased neutrophil apoptosis/phagocytosis and poor prognosis in non-small-cell lung cancer patients.
    Br J Cancer. 2017 Jun 20. doi: 10.1038/bjc.2017.
    PubMed     Text format     Abstract available


  49. BAHLEDA R, Grilley-Olson JE, Govindan R, Barlesi F, et al
    Phase I dose-escalation studies of roniciclib, a pan-cyclin-dependent kinase inhibitor, in advanced malignancies.
    Br J Cancer. 2017;116:1505-1512.
    PubMed     Text format     Abstract available


    May 2017
  50. KAZDAL D, Harms A, Endris V, Penzel R, et al
    Prevalence of somatic mitochondrial mutations and spatial distribution of mitochondria in non-small cell lung cancer.
    Br J Cancer. 2017 May 30. doi: 10.1038/bjc.2017.
    PubMed     Text format     Abstract available


  51. KOINIS F, Agelaki S, Karavassilis V, Kentepozidis N, et al
    Second-line pazopanib in patients with relapsed and refractory small-cell lung cancer: a multicentre phase II study of the Hellenic Oncology Research Group.
    Br J Cancer. 2017 May 16. doi: 10.1038/bjc.2017.
    PubMed     Text format     Abstract available


    March 2017
  52. MACLEOD AK, Acosta-Jimenez L, Coates PJ, McMahon M, et al
    Aldo-keto reductases are biomarkers of NRF2 activity and are co-ordinately overexpressed in non-small cell lung cancer.
    Br J Cancer. 2017 Mar 21. doi: 10.1038/bjc.2017.
    PubMed     Text format    


  53. MURUGANANDAN S, Alfonso H, Franklin P, Shilkin K, et al
    Comparison of outcomes following a cytological or histological diagnosis of malignant mesothelioma.
    Br J Cancer. 2017;116:703-708.
    PubMed     Text format     Abstract available


  54. MALAPELLE U, Mayo de-Las-Casas C, Rocco D, Garzon M, et al
    Development of a gene panel for next-generation sequencing of clinically relevant mutations in cell-free DNA from cancer patients.
    Br J Cancer. 2017;116:802-810.
    PubMed     Text format     Abstract available


    January 2017
  55. BOUCHARD G, Therriault H, Geha S, Bujold R, et al
    Radiation-induced lung metastasis development is MT1-MMP-dependent in a triple-negative breast cancer mouse model.
    Br J Cancer. 2017 Jan 19. doi: 10.1038/bjc.2016.
    PubMed     Text format     Abstract available


  56. WU YL, Sequist LV, Hu CP, Feng J, et al
    EGFR mutation detection in circulating cell-free DNA of lung adenocarcinoma patients: analysis of LUX-Lung 3 and 6.
    Br J Cancer. 2017;116:175-185.
    PubMed     Text format     Abstract available


  57. KIM H, Sung JY, Park EK, Kho S, et al
    Regulation of anoikis resistance by NADPH oxidase 4 and epidermal growth factor receptor.
    Br J Cancer. 2017;116:370-381.
    PubMed     Text format     Abstract available


    September 2016
  58. HUANG J, Mondul AM, Weinstein SJ, Koutros S, et al
    Serum metabolomic profiling of prostate cancer risk in the prostate, lung, colorectal, and ovarian cancer screening trial.
    Br J Cancer. 2016 Sep 27. doi: 10.1038/bjc.2016.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Lung Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: